Presequence translocase-associated motor subunit PAM16 (PAM16) (PAM16)

Presequence translocase-associated motor subunit PAM16 (PAM16), also known as MAGMAS, is an essential component of the mitochondrial protein import machinery located within the inner mitochondrial membrane [1]. It serves as a critical regulator of the TIM23 translocase complex by forming a stable heterodimer with PAM18, which in turn modulates the ATPase activity of mitochondrial Hsp70 (mtHsp70) [1, 4]. This interaction is vital for the energy-driven translocation of nuclear-encoded proteins into the mitochondrial matrix, a process necessary for mitochondrial biogenesis and cellular metabolism [4, 5]. Clinically, mutations in the PAM16 gene are the underlying cause of Spondylometaphyseal dysplasia, Schmidt type, a rare genetic disorder characterized by severe skeletal abnormalities and short stature [2]. Furthermore, PAM16 is frequently overexpressed in various malignancies, including prostate and pituitary cancers, where it plays a role in promoting cell survival and conferring resistance to pro-apoptotic stimuli [3]. Due to its role in maintaining mitochondrial integrity in tumor cells, PAM16 has emerged as a viable therapeutic target in oncology [3]. Experimental small-molecule inhibitors, such as BTG-0028, have been developed to disrupt PAM16 function, leading to mitochondrial dysfunction and the induction of apoptosis in cancer cells [3, 5].

Other names

MAGMASMitochondria-associated granulocyte-macrophage colony-stimulating factor signaling moleculeTIM16TIMM16Presequence translocase-associated motor 16

Inhibition of the PAM16-PAM18 interaction to disrupt mitochondrial protein import and induce apoptosis in cancer cells.